Chao J - Search Results

1

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.

Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Lee J, Castro HR, Mansoor W, Braghiroli MI, Karaseva N, Caglevic C, Villanueva L, Goekkurt E, Satake H, Enzinger P, Alsina M, Benson A, Chao J, Ko AH, Wainberg ZA, Kher U, Shah S, Kang SP, Tabernero J. Shitara K, et al. Among authors: chao j. JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370. JAMA Oncol. 2020. PMID: 32880601 Free PMC article. Clinical Trial.

2

Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.

Chung V, Frankel P, Lim D, Yeon C, Leong L, Chao J, Ruel N, Luevanos E, Koehler S, Chung S, Lau SC, Fakih MG. Chung V, et al. Among authors: chao j. Oncology. 2016;90(6):307-12. doi: 10.1159/000445297. Epub 2016 Apr 20. Oncology. 2016. PMID: 27093189 Clinical Trial.

3

Moving molecular subtypes to the clinic in gastric cancer.

Chao J, Lee J, Klempner SJ. Chao J, et al. Transl Cancer Res. 2016 Jun;5(Suppl 1):S25-S30. doi: 10.21037/tcr.2016.05.21. Transl Cancer Res. 2016. PMID: 28781963 Free PMC article. No abstract available.

4

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.

Chung V, Kos FJ, Hardwick N, Yuan Y, Chao J, Li D, Waisman J, Li M, Zurcher K, Frankel P, Diamond DJ. Chung V, et al. Among authors: chao j. Clin Transl Oncol. 2019 Mar;21(3):363-372. doi: 10.1007/s12094-018-1932-2. Epub 2018 Aug 9. Clin Transl Oncol. 2019. PMID: 30094792 Free PMC article. Clinical Trial.

5

Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.

Klempner SJ, Bhangoo MS, Luu HY, Kim ST, Chao J, Kim KM, Lee J. Klempner SJ, et al. Among authors: chao j. J Gastrointest Oncol. 2018 Dec;9(6):1198-1206. doi: 10.21037/jgo.2018.09.04. J Gastrointest Oncol. 2018. PMID: 30603142 Free PMC article.

6

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M. Schrock AB, et al. Among authors: chao j. Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134. Ann Oncol. 2019. PMID: 31038663 Free article.

7

Real-World Outcomes and Factors Associated With the Second-Line Treatment of Patients With Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma.

Barzi A, Hess LM, Zhu YE, Liepa AM, Sugihara T, Beyrer J, Chao J. Barzi A, et al. Among authors: chao j. Cancer Control. 2019 Jan-Dec;26(1):1073274819847642. doi: 10.1177/1073274819847642. Cancer Control. 2019. PMID: 31056940 Free PMC article.

8

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J. Klempner SJ, et al. Among authors: chao j. Oncologist. 2019 Nov;24(11):1462-1468. doi: 10.1634/theoncologist.2019-0121. Epub 2019 Jun 27. Oncologist. 2019. PMID: 31249137 Free PMC article.

9

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Corvera C, Das P, Denlinger CS, Enzinger PC, Fanta P, Farjah F, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Leong S, Ly QP, Matkowskyj KA, McNamara M, Mulcahy MF, Paluri RK, Park H, Perry KA, Pimiento J, Poultsides GA, Roses R, Strong VE, Wiesner G, Willett CG, Wright CD, McMillian NR, Pluchino LA. Ajani JA, et al. Among authors: chao j. J Natl Compr Canc Netw. 2019 Jul 1;17(7):855-883. doi: 10.6004/jnccn.2019.0033. J Natl Compr Canc Netw. 2019. PMID: 31319389

10

High-level FGFR2 amplification is associated with poor prognosis and Lower response to chemotherapy in gastric cancers.

Hur JY, Chao J, Kim K, Kim ST, Kim KM, Klempner SJ, Lee J. Hur JY, et al. Among authors: chao j. Pathol Res Pract. 2020 Apr;216(4):152878. doi: 10.1016/j.prp.2020.152878. Epub 2020 Feb 13. Pathol Res Pract. 2020. PMID: 32089408 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,159 results

Search Page